This may be due to the fact that KRAS-G12D patients have a higher TNM stage and more patients lose the chance of surgery when pancreatic cancer is diagnosed, resulting in a decrease in the proportion of KRAS-G12D patients among surgical patients (18). This evidence concerns the gene KRAS and familial pancreatic carcinoma.